---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-008273"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-03-02T23:59:59+00:00"
generated_at: "2026-06-27T02:32:19.036105+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio hires Alethia Young as CFO; Gutry steps down as PFO/PAO

## Summary
- Alethia Young appointed CFO effective April 1, 2022; previously senior biotech analyst at Cantor Fitzgerald.
- Base salary $450,000, target cash bonus 40% of salary, signing bonus $170,000.
- Relocation assistance $50,000/quarter for 12 months; initial option grant of 350,000 shares.
- Philip Gutry resigns as principal financial officer and principal accounting officer effective April 1, remains Chief Business Officer.
- Ms. Young will oversee finance, investor relations, corporate communications, and corporate strategy.

## SEC filing metadata
- accession: 0001564590-22-008273
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-03-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000156459022008273/0001564590-22-008273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000156459022008273/grph-8k_20220302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-008273
- JSON: https://secwatch.observer/filing/0001564590-22-008273.json
- Plain text: https://secwatch.observer/filing/0001564590-22-008273.txt

## Key facts
- Executive change
  Alethia Young was appointed as Chief Financial Officer at LENZ Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 2, 2022, Graphite Bio, Inc. (the “Company”) announced the hiring and appointment of Alethia Young as Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000156459022008273/0001564590-22-008273-index.htm
- Executive change
  Philip P. Gutry resigned as principal financial officer and principal accounting officer at LENZ Therapeutics, Inc..
  - Action: resigned
  - Role: principal financial officer and principal accounting officer
  source text: Effective as of April 1, 2022, Philip P. Gutry, who is currently serving as Chief Business Officer, Head of Finance & Investor Relations, principal financial officer and principal accounting officer of the Company, will resign from his positions as the Company’s Head of Finance & Investor Relations, principal financial officer and principal accounting officer and will continue to serve as Chief Business Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000156459022008273/0001564590-22-008273-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.